The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cronos Australia (CAU) has launched its cannabidiol-based sports gel range, FCTR
  • For now, the range includes a warm gel and a cool gel which are designed to help a wide range of athletes with recovery
  • FCTR will initially be sold in Hong Kong and Japan and is not yet available in Australia due to regulatory reasons
  • To speed up distribution, Cronos has signed a sales agency agreement with SS Outdoor
  • On market close for the long weekend, Cronos is up 12.5 per cent and is trading at 13.5 cents per share

Cronos Australia (CAU) has launched its cannabidiol-based sports gel range, FCTR.

FCTR is the company’s second consumer brand, following Bathing Shed, and will initially be sold in Hong Kong and Japan. Due to regulatory reasons, FCTR is not yet available in Australia.

The product is designed to be a recovery for a wide range of athletes. The first two products being launched is a warm gel and cool gel.

FCTR Warm Gel has a warming sensation when applied to the skin and may aid in recovery, whereas FCTR Cool Gel has a cooling sensation when applied to the skin.

Both products are entirely formulated and manufactured in Japan and contain compliant CBD in a rapidly absorbed and residue-free gel.

The products will retail for HKD190 (roughly A$32.40) in Hong Kong and JPY2,273 (roughly A$27.20) in Japan.

To speed up the distribution of FCTR, Cronos has signed a sales agency agreement with SS Outdoor, a Sure Step Asia group company.

Cronos Australia’s Director Nick Mulcahy says elite athletes and their coaching teams have three key concerns about CBD topical products.

“Firstly, they must be pure and compliant with World Anti-Doping Agency guidelines. Secondly, CBD must be made more affordable. Thirdly, athletes want a CBD sports product with the same design, usability and effectiveness standards that they expect from the rest of their gear,” he said.

“With our first two FCTR products, we believe we have successfully addressed each of those concerns,” he added.

On market close for the long weekend, Cronos is up 12.5 per cent and is trading at 13.5 cents per share.

CAU by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…